Case Report

Pneumocystis pneumonia during Postoperative Adjuvant Chemotherapy for Breast Cancer

Tsuyoshi Shinohara, 1 Makito Yasui, 2 Hiroyuki Yamada, 1 Yoshiro Fujimori, 1 and Kiyofumi Yamagishi 1

1 Department of Surgery, Hokushin General Hospital, 63-5-1 Nishi, Nakano-city, Nagano 383-8505, Japan
2 Department of Respiratory Medicine, Hokushin General Hospital, 63-5-1 Nishi, Nakano-city, Nagano 383-8505, Japan

Correspondence should be addressed to Tsuyoshi Shinohara; t-sinohara@hokushin-hosp.jp

Received 25 March 2013; Accepted 8 May 2013

Academic Editors: M. Romkes, Y. Yokoyama, and N. Yoshimura

Copyright © 2013 Tsuyoshi Shinohara et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

A 72-year-old woman underwent a mastectomy with one-stage breast reconstruction using silicone implant for right breast cancer. Postoperatively, she had received adjuvant chemotherapy with fluorouracil, epirubicin, and cyclophosphamide (FEC regimen). She was admitted for febrile neutropenia after the third course of chemotherapy. She remained febrile for a week, and she complained of dyspnea on hospital day 8. Computed tomography scan demonstrated widespread patchy ground glass changes in both lungs and serum \((1 \rightarrow 3)-\beta-D\)-glucan was elevated to 20 pg/mL. Oral trimethoprim-sulfamethoxazole was started on the strong clinical suspicion of PCP, and the patient subsequently made a rapid recovery from fever and dyspnea.

1. Introduction

The efficacy of cyclophosphamide, methotrexate, and fluorouracil (CMF regimen) as an adjuvant chemotherapy for breast cancer was first reported by Bonadonna et al. in 1976 [1]. Since then, several trials have demonstrated that adjuvant systemic combination chemotherapy can reduce the risk of recurrence and prolong overall survival among patients with breast cancer [2–5].

Anthracyclines are an important component of adjuvant polychemotherapy, and fluorouracil, epirubicin, and cyclophosphamide (FEC regimen) have been established as one of the standard regimens for postoperative breast cancer patients. While the most common adverse effects in patients treated by FEC are nausea, leukocytopenia, and alopecia, opportunistic infections are not thought to be common in this population [6–8].

We describe here the case of a patient with severe Pneumocystis pneumonia (formerly Pneumocystis carinii pneumonia) (PCP) during postoperative adjuvant chemotherapy with FEC.

2. Case Presentation

A 72-year-old postmenopausal woman visited our hospital for further evaluation to the following mammography at a medical checkup. The mammography had revealed a microlobulated tumor accompanied by fine linear branching calcifications showing a segmental distribution in the right breast.

No mass was palpable in the right breast, but core needle biopsy of the tumor under ultrasonography showed malignant cells, which proved negative for hormonal receptors. Primary breast cancer was diagnosed based on the radiological and pathological findings. Total mastectomy with sentinel lymph node biopsy and a one-stage immediate breast reconstruction with a permanent silicone implant were performed.

Pathological examination of the resected specimens revealed invasive ductal carcinoma (scirrhous carcinoma) with intraductal spread measuring \(6.0 \times 5.0\) cm, which was negative for human epidermal growth factor receptor type 2 (HER 2) (Figure 1). Sentinel lymph node biopsy yielded negative results.
The patient was scheduled to receive six cycles of adjuvant chemotherapy, with each cycle comprising 5-Fluouracil at 500 mg/m², Epirubicin at 100 mg/m², and Cyclophosphamide at 500 mg/m² on day 1 within a 3-week period. The patient received 9.9 mg of intravenous dexamethasone on the day of chemotherapy and oral dexamethasone at 4 mg twice daily for 3 days after chemotherapy administration. The patient presented to our hospital due to fever and general fatigue 14 days after completing the third course of chemotherapy with FEC. Laboratory studies revealed a white blood cell count of 700/mm³, with 59% neutrophils. The patient was admitted for febrile neutropenia and intravenous cefepime dihydrochloride was commenced at 2.0 g two times daily. Granulocyte colony stimulating factor (G-CSF) therapy was also administered on hospital day 0 (Nartograsitim 50 μg subcutaneous injection). On hospital day 1, neutrophil count had recovered and G-CSF therapy was stopped. She remained febrile despite empiric antibiotic therapy for a week but showed no symptoms other than fever. On hospital day 8, the patient complained of severe dyspnea. Oxygen saturation was found to be 75% at rest on room air, rising to >90% with 100% O₂ by nasal cannula. However, she showed no respiratory symptoms, including cough. Computed tomography (CT) demonstrated widespread patchy ground glass changes in both lungs (Figure 2). White blood cells and absolute neutrophil count were 7300/μL and 6490/μL, respectively, and serum (1→3)-β-D-glucan level was elevated to 20 pg/mL (normal, 0–11 pg/mL). Microscopic sputum examination was uninformative and blood cultures for bacteria and fungi yielded negative results. Viral serological testing for cytomegalovirus antigen pp65 was likewise negative. Examination of bronchoalveolar lavage fluid (BALF) was not performed because of severe respiratory failure. Serological testing for human immunodeficiency virus (HIV) was negative. After collecting sputum for polymerase chain reaction (PCR), she was treated with oral trimethoprim-sulfamethoxazole (TMP/SMX) in consideration of the possibility of PCP. Intravenous meropenem hydrate, fosfluconazole, and oral prednisolone were administered simultaneously. Although we obtained negative results for *Pneumocystis jiroveci* from sputum by PCR, the diagnosis of PCP was made based on the clinical course. Her temperature rapidly dropped to normal and dyspnea disappeared 4 days after starting TMP/SMX therapy. Chest CT after 8 days of TMP/SMX showed considerable improvement of pulmonary infiltrations (Figure 3). TMP/SMX therapy discontinued after 16 days. She was discharged without symptoms 32 days after the admission (Figure 4).
Although examination of BALF offers good sensitivity, sensitivity of induced sputum is low, reported as about 50% BALF or lung tissue, since 
P. jiroveci from collected specimens such as induced sputum, bronchoalveolar lavage is invasive and requires microscopic examination to identify. Therefore, vital. However, the diagnosis of PCP is difficult in HIV-negative patients [9]. Early diagnosis and therapy are crucial. In retrospective series, a daily corticosteroid dose equivalent to 16–30 mg of prednisone for a period of 8–12 weeks was associated with a significant risk of PCP in patients without AIDS [23]. Prophylactic administration of dexamethasone for antiemetic effect is recommended and well accepted, and the present patient had received only intermittent dexamethasone given for 4 days at the beginning of each cycle of chemotherapy. Although dexamethasone has approximately 7.5 times anti-inflammatory effect of prednisone, it is unknown whether short-duration, intermittent dosing with dexamethasone for antiemesis represents a risk factor for the development of opportunistic infections.

PCP occurs most frequently when the T-helper cell count (CD4+) is <200 cells/mm³ [24, 25]. Lymphocyte depletion in patients receiving chemotherapy may correlate with the frequency and intensity of the dose [13], but clinicians tend to pay attention only to neutropenia, as represented by febrile neutropenia. Lymphocyte depletion may be induced more frequently or severely during dose-dense chemotherapy [26]. Although G-CSF therapy may immediately result in adequate recover from neutropenia, the degree of lymphocyte depletion may remain unaltered [26].

In conclusion, clinicians must always keep in mind that life-threatening PCP can be induced by dose-dense chemotherapy, even in the form of adjuvant chemotherapy in postoperative patients without cancer.

3. Discussion

PCP is an opportunistic infection caused by Pneumocystis jiroveci, a fungal organism with tropism for lung parenchyma [9]. PCP is predominantly seen in patients with acquired immunodeficiency syndrome (AIDS) but can also occur in patients with cancer. However, among patients with cancer, this disease is particularly common with hematological malignancies such as acute leukemia or malignant lymphoma and is less common in patients with solid tumors [10, 11]. Cases of PCP in patients with breast cancer are rare and most previously described patients with breast cancer who developed PCP were patients with high-dose chemotherapy for metastases [12–16]. Only two previous reports have described PCP occurring in breast cancer patients receiving postoperative adjuvant chemotherapy [17, 18].

PCP is well known as a major cause of mortality and morbidity in immunocompromised individuals. Outcomes appear worse in HIV-negative patients than in HIV-positive ones [7, 16, 18, 19], with a morbidity rate of 30%–60% in HIV-negative patients [9]. Early diagnosis and therapy are therefore vital. However, the diagnosis of PCP is difficult because microscopic examination is required to identify P. jiroveci from collected specimens such as induced sputum, BALF or lung tissue, since P. jiroveci cannot be cultured. The sensitivity of induced sputum is low, reported as about 50% [20]. Although examination of BALF offers good sensitivity, bronchoalveolar lavage is an invasive procedure with its own associated morbidity, particularly for patients with severe respiratory failure. Measurement of serum (1 → 3)-β-D-glucan levels is a noninvasive and useful tool for the diagnosis of PCP [21, 22], but (1 → 3)-β-D-glucan is a component of the cell wall in not only P. jiroveci but also various other fungi and thus reportedly offers only 76%–96% specificity [21]. Clinicians must therefore sometimes decide whether to treat PCP empirically on the basis of characteristic clinical and radiological presentations.

Corticosteroids are thought to be one of the strongest predisposing factors for the development of PCP in patients who are not infected with HIV. In retrospective series, a daily corticosteroid dose equivalent to 16–30 mg of prednisone for a period of 8–12 weeks was associated with a significant risk of PCP in patients without AIDS [23]. Prophylactic administration of dexamethasone for antiemetic effect is recommended and well accepted, and the present patient had received only intermittent dexamethasone given for 4 days at the beginning of each cycle of chemotherapy. Although dexamethasone has approximately 7.5 times anti-inflammatory effect of prednisone, it is unknown whether short-duration, intermittent dosing with dexamethasone for antiemesis represents a risk factor for the development of opportunistic infections.

PCP occurs most frequently when the T-helper cell count (CD4+) is <200 cells/mm³ [24, 25]. Lymphocyte depletion in patients receiving chemotherapy may correlate with the frequency and intensity of the dose [13], but clinicians tend to pay attention only to neutropenia, as represented by febrile neutropenia. Lymphocyte depletion may be induced more frequently or severely during dose-dense chemotherapy [26]. Although G-CSF therapy may immediately result in adequate recovery from neutropenia, the degree of lymphocyte depletion may remain unaltered [26].

In conclusion, clinicians must always keep in mind that life-threatening PCP can be induced by dose-dense chemotherapy, even in the form of adjuvant chemotherapy in postoperative patients without cancer.

Conflict of Interests

The authors declare that there is no conflict of interests.

References

[1] G. Bonadonna, E. Busamolino, P. Valagussa et al., “Combination chemotherapy as an adjuvant treatment in operable breast cancer,” The New England Journal of Medicine, vol. 294, no. 8, pp. 405–410, 1976.

[2] G. Bonadonna, P. Valagussa, A. Moliterni, M. Zambetti, and C. Brambilla, “Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up,” The New England Journal of Medicine, vol. 332, no. 14, pp. 901–906, 1995.

[3] Early Breast Cancer Trialists’ Collaborative Group, “Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomized trials,” The Lancet, vol. 365, no. 9472, pp. 1687–1717, 2005.

[4] Early Breast Cancer Trialists’ Collaborative Group, “Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy,” The Lancet, vol. 339, no. 8785, pp. 71–85, 1992.

[5] A. Goldhirsh, J. H. Glick, R. D. Gelber, A. S. Coates, B. Thurlimann, and H. J. Senn, “Meeting highlight: international expert consensus on the primary therapy of early breast cancer,” Annals of Oncology, vol. 16, no. 10, pp. 1569–1583, 2005.

[6] P. Pacini, M. Rinaldini, R. Alighi et al., “FEC (5-fluorouracil, epirubicin, and cyclophosphamide) versus EM (epirubicin and mitomycin-C) with or without lonidamine as first-line treatment for advanced breast cancer. A multicentric randomised study. Final results,” European Journal of Cancer, vol. 36, no. 8, pp. 966–973, 2000.
[7] P. W. Yan, X. E. Huang, Y. Jiang et al., “Clinical comparison of safety and efficacy of vinorelbine/epirubicin (NE) with fluorouracil/epirubicin/cyclophosphamide (FEC),” *Asian Pacific Journal of Cancer Prevention*, vol. 11, no. 4, pp. 1115–1118, 2010.

[8] P. Fumoleau, P. Kerbrat, P. Romestaing et al., “Randomized trial comparing six versus three cycles of epirubicin-based adjuvant chemotherapy in premenopausal, node-positive breast cancer patients: 10-year follow-up results of the French adjuvant study group 01 trial,” *Journal of Clinical Oncology*, vol. 21, no. 2, pp. 298–305, 2003.

[9] C. F. Thomas Jr. and A. H. Limper, “Pneumocystis pneumonia,” *The New England Journal of Medicine*, vol. 350, no. 24, pp. 2487–2498, 2004.

[10] K. A. Sepkowitz, “Opportunistic infections in patients with and patients without acquired immunodeficiency syndrome,” *Clinical Infectious Diseases*, vol. 34, no. 8, pp. 1098–1107, 2002.

[11] K. A. Sepkowitz, A. E. Brown, E. E. Telzak, S. Gottlieb, and D. Armstrong, “Pneumocystis carinii pneumonia among patients without AIDS at a cancer hospital,” *Journal of the American Medical Association*, vol. 267, no. 6, pp. 832–837, 1992.

[12] R. El Ghouli, S. M. Eckardt, S. Mukhopadhyay, and R. W. Ashton, “Fever and dyspnea in a 61-year-old woman with metastatic breast cancer,” *Chest*, vol. 136, no. 2, pp. 634–638, 2009.

[13] M. H. Kulke and E. A. Vance, “Pneumocystis carinii pneumonia in patients receiving chemotherapy for breast cancer,” *Clinical Infectious Diseases*, vol. 25, no. 2, pp. 215–218, 1997.

[14] Y. Koibuchi, Y. Iino, T. Yokoe, T. Oyama, T. Nakajima, and Y. Morishita, “Pneumocystis carinii pneumonia during treatment for recurrent breast cancer: a case report,” *Japanese Journal of Clinical Oncology*, vol. 25, no. 5, pp. 218–221, 1995.

[15] I. Genvrresse, K. Akrivakis, B. Flath, E. Spath-Schwalbe, and K. Possinger, “Pneumocystis carinii pneumonia in breast cancer,” *Annals of Oncology*, vol. 9, no. 5, pp. 573–574, 1998.

[16] A. Klippstein, C. P. Schneider, H. G. Sayer, and K. Höflken, “Pneumocystis carinii pneumonia as a complication of bendamustine monotherapy in a patient with advanced progressive breast cancer,” *Journal of Cancer Research and Clinical Oncology*, vol. 129, no. 5, pp. 316–319, 2003.

[17] S. M. Tolaney, I. Najita, E. P. Winer, and H. J. Burstein, “Lymphopenia associated with adjuvant anthracycline/taxane regimens,” *Clinical Breast Cancer*, vol. 8, no. 4, pp. 352–356, 2008.

[18] S. M. Tolaney, A. H. Partridge, R. G. Sheib, H. J. Burstein, and E. P. Winer, “Pneumocystis carinii pneumonia during dose-dense chemotherapy for breast cancer,” *Journal of Clinical Oncology*, vol. 24, no. 33, pp. 5330–5331, 2006.

[19] J. A. Kovacs, J. W. Hiemenz, A. M. Macher et al., “Pneumocystis carinii pneumonia: A comparison between patients with acquired immunodeficiency syndrome and patients with other immunodeficiencies,” *Annals of Internal Medicine*, vol. 100, no. 5, pp. 663–671, 1984.

[20] M. Cruciani, P. Marcati, M. Malena, O. Bosco, G. Serpelloni, and C. Mengoli, “Meta-analysis of diagnostic procedures for Pneumocystis carinii pneumonia in HIV-1-infected patients,” *European Respiratory Journal*, vol. 20, no. 4, pp. 982–989, 2002.

[21] J. Held, M. S. Koch, U. Reischl, T. Danner, and A. Serr, “Serum (1 → 3)-β-D-glucan measurement as an early indicator of Pneumocystis jirovecii pneumonia and evaluation of its prognostic value,” *Clinical Microbiology and Infection*, vol. 17, no. 4, pp. 595–602, 2011.

[22] V. Del Bono, A. Mularoni, E. Furfaro et al., “Clinical evaluation of a (1,3)-β-D-glucan assay for presumptive diagnosis of Pneumocystis jiroveci pneumonia in immunocompromised patients,” *Clinical and Vaccine Immunology*, vol. 16, no. 10, pp. 1524–1526, 2009.

[23] S. H. Yale and A. H. Limper, “Pneumocystis carinii pneumonia in patients without acquired immunodeficiency syndrome: Associated illnesses and prior corticosteroid therapy,” *Mayo Clinic Proceedings*, vol. 71, no. 1, pp. 5–13, 1996.

[24] J. Phair, A. Munoz, R. Detels et al., “The risk of Pneumocystis carinii pneumonia among men infected with human immunodeficiency virus type 1,” *The New England Journal of Medicine*, vol. 322, no. 3, pp. 161–165, 1990.

[25] H. Masur, J. E. Kaplan, and K. K. Holmes, “Guideline for preventing opportunistic infections among HIV-infected persons-2002,” *Annals of Internal Medicine*, vol. 137, no. 5, pp. 435–478, 2002.

[26] C. L. Mackall, T. A. Fleisher, M. R. Brown et al., “Lymphocyte depletion during treatment with intensive chemotherapy for cancer,” *Blood*, vol. 84, no. 7, pp. 2221–2228, 1994.